AFMD News and Press, Affimed N.V. From 02/08/21

Affimed N.V. (AFMD) discloses following passive stake:Point72 Asset Management, Point72 Capital Advisors Inc. and Mr. Cohen beneficially own ~5.64M shares, constituting 4.8% stake.Cubist Systematic Strategies and Mr. Cohen beneficially own 177,487 shares, constituting 0.2% stake.Stock ri...

Affimed N.V. (AFMD) has surged ~10.6% in the premarket after announcing that it has entered a research collaboration with Roche (RHHBY) to study its innate cell engager (ICE®) AFM24 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®).As per t...

Heidelberg, Germany, February 3, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has entered into a clinical research collaboration with Roche to explore t...

Heidelberg, Germany, January 15, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the closing of its ...

Affimed (AFMD) has priced its public offering of ~16.7M common shares at $6.00/share.Expected net proceeds are ~$94M.Underwriters' over-allotment is an additional 2.5M shares.Closing date is January 15.Shares down 9% premarket.Previously, Jan.12: Affimed N.V. initiates equity offeri...

Heidelberg, Germany, January 13, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the pricing of its previo...

Gainers: [[MTRX]] +24.8%. [[FARM]] +19.1%. [[STIM]] +15.9%. [[EXFO]] +13.1%. [[FSI]] +11.1%.Losers: [[PRTY]] -12.3%. [[QLI]] -9.2%. [[URBN]] -7.8%. [[PRVB]] -7.4%. [[AFMD]] -5.6%. For further details see: MTRX, FARM, PRTY and QLI among after-hours movers

Affimed N.V. (AFMD) says it has started an underwritten public offering of its common shares, where underwriters will have an overallotment option to purchase up to additional 15% of share offering.Price, size and terms not yet determined.Previously (Jan. 11): Affimed inks €2...

Affimed (AFMD) has entered into a debt financing agreement with Silicon Valley Bank German Branch ((SVB)) which provides Affimed with up to €25M in term loans. “This financing will help support the broad development strategy for our ICE molecules as monotherapies and in com...

Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the 39th Annual J...